Over 10,000 patients,a fatality rate more than 97% LOWER than France’s – an exceptional case for early treatment with a drug regimen including HCQ & AZM.
Hydroxychloroquine is an effective molecule against COVID-19 infection, many RCTs and observational studies, affirmed the benefits on virological clearance.
No cases of sudden death were observed. From publication, we have treated 3,119 patients with HCQ-AZ for at least three days.
While numerous studies have now proven this to be so, and the practical experiences of several doctors with numerous patients have shown that, as part of a package of quality outpatient care, the drug can play an important role in reducing the need for hospitalization and the mortality risk.
Professor Raoult had very quickly sent a “warning letter” to the newspaper about this study which seemed to him incomplete and including too much bias.
“Wednesday evening, I take the first meds. Thursday morning, I feel that the viral load has already decreased and most of the symptoms have improved.”
We believe this study is fatally flawed: “Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: a systematic review and meta-analysis”.
A Belgian study has just been published, on 8,000 patients, and concludes that hydroxychloroquine reduces mortality by 30%
“Hydroxychloroquine can be prescribed to adults and children of all ages. It can also be safely taken by pregnant women and nursing mothers.”
